Neptune Technologies & Bioressources is Nominated as Finalist for the Nutraceutical & Business Technology Awards 2011 and Prolon
14 April 2011 - 10:00PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) is proud to announce that it is a
finalist for the Nutraceutical & Business Technology (NBT)
Awards 2011, in the category of Outstanding Application in Health
Management.
After much deliberation and due-diligence, the judges submitted
a shortlist of finalists. Neptune is one out of five companies
announced as a finalist for the NBT Awards, in the much esteemed
category of Outstanding Application in Health Management. The high
standard of the NBT Awards has contributed to making this event a
great success. The winners will be announced on the night of the
Awards at the Gala dinner to be held on Wednesday, May 11th during
the nutraceutical event of Vitafoods Europe in Geneva. ''We are
very proud to be a finalist for an NBT award, especially in the
Outstanding Application in Health Management category. Being in the
top finalists for this category, along with industry pioneers,
shows a worldwide recognition of the benefits of NKO®,'' stated
Sabrina Di Blasio, Director, Marketing.
On another subject, Neptune prolongs its IR agreement with
CEOcast to continue the development of an exhaustive IR strategy in
the US. As per the extension of the IR agreement, CEOcast has been
granted options to purchase 25,000 common shares of Neptune at a
price of $2.50 per share. The options will vest in equal amounts at
a rate of 15% per quarter with a three-year term expiring on March
15th, 2014.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3
phospholipids. Phospholipids are the major component of cell
membranes and are essential for all vital cell processes. They are
one of the principal constituents of High Density Lipoprotein (good
cholesterol) and, as such, play an important role in modulating
cholesterol efflux. Acasti Pharma's proprietary novel phospholipids
carry and functionalize the polyunsaturated omega-3 fatty acids EPA
and DHA, which have been shown to have substantial health benefits
and which are stabilized by potent antioxidants. Acasti Pharma is
focusing initially on treatments for chronic cardiovascular
conditions within the over-the-counter, medical food and
prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
(888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024